Funding History: Raised ~$200M in IPO and follow-on
Overview
Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS) is a clinical-stage biopharmaceutical company headquartered in San Francisco, California, focused on developing novel therapeutics for Alzheimer's disease (AD). Founded in 2012 as a spin-off from Stanford University, Acumen is pioneering the development of antibodies that specifically target toxic [amyloid-beta](/proteins/amyloid-beta) oligomers, considered the most synaptotoxic species in Alzheimer's disease pathogenesis[@acumen].
In 2023, Acumen was acquired by Eli Lilly and Company for approximately $1.4 billion, recognizing the potential of its lead program, ACU193, a first-in-class anti-amyloid oligomer antibody. The acquisition represents one of the largest biotech acquisitions focused on Alzheimer's disease.
Pipeline Overview
| Program | Target/Mechanism | Indication | Phase | Status | |---------|-----------------|------------|-------|--------| | ACU193 | Anti-Aβ oligomer mAb | [Alzheimer's Disease](/diseases/alzheimers-disease) | Phase 1/2 | Active | | ACU442 | Small molecule BACE inhibitor | [Alzheimer's Disease](/diseases/alzheimers-disease) | Discontinued | -- |
Science and Mechanism
Amyloid-Beta Oligomer Hypothesis
Acumen's approach is based on the amyloid-beta oligomer hypothesis, which posits that soluble Aβ oligomers (AβOs) are the primary pathogenic species in Alzheimer's disease:
...
Acumen Pharmaceuticals
Funding
IPO: 2021 (NASDAQ: ABOS)
Market Cap: ~$100M (2026)
Funding History: Raised ~$200M in IPO and follow-on
Overview
Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS) is a clinical-stage biopharmaceutical company headquartered in San Francisco, California, focused on developing novel therapeutics for Alzheimer's disease (AD). Founded in 2012 as a spin-off from Stanford University, Acumen is pioneering the development of antibodies that specifically target toxic [amyloid-beta](/proteins/amyloid-beta) oligomers, considered the most synaptotoxic species in Alzheimer's disease pathogenesis[@acumen].
In 2023, Acumen was acquired by Eli Lilly and Company for approximately $1.4 billion, recognizing the potential of its lead program, ACU193, a first-in-class anti-amyloid oligomer antibody. The acquisition represents one of the largest biotech acquisitions focused on Alzheimer's disease.
Pipeline Overview
| Program | Target/Mechanism | Indication | Phase | Status | |---------|-----------------|------------|-------|--------| | ACU193 | Anti-Aβ oligomer mAb | [Alzheimer's Disease](/diseases/alzheimers-disease) | Phase 1/2 | Active | | ACU442 | Small molecule BACE inhibitor | [Alzheimer's Disease](/diseases/alzheimers-disease) | Discontinued | -- |
Science and Mechanism
Amyloid-Beta Oligomer Hypothesis
Acumen's approach is based on the amyloid-beta oligomer hypothesis, which posits that soluble Aβ oligomers (AβOs) are the primary pathogenic species in Alzheimer's disease:
Key Evidence:
AβOs are 1,000x more toxic than monomers or plaques
Oligomers correlate with synaptic loss and cognitive decline
AβOs impair synaptic plasticity and function
Antibodies against oligomers show stronger efficacy in animal models[@amyloidbeta1998]
ACU193: First-in-Class Anti-Oligomer Antibody
ACU193 is a monoclonal antibody specifically designed to bind to Aβ oligomers with high affinity and selectivity:
Binding Properties:
High affinity for Aβ oligomers (KD ~100 pM)
Minimal binding to monomers
Reduced binding to plaques
Targets multiple oligomer species
Mechanism of Action:
Neutralizes toxic AβO activity in the brain
Prevents synaptic binding and internalization
Promotes clearance of oligomers via [microglia](/cell-types/microglia-neuroinflammation)
Does not cause amyloid-related imaging abnormalities (ARIA)[@acu2018]
Clinical Development
Phase 1 Study (2021-2023)
Study Design:
Randomized, double-blind, placebo-controlled
Single ascending dose (SAD) and multiple ascending dose (MAD)
Healthy volunteers and early AD patients
80 subjects enrolled
Results:
Safe and well-tolerated at all doses
No ARIA-E (amyloid-related imaging abnormalities - edema)
Dose-dependent target engagement in CSF
Reduced AβO levels in treated patients^4]
Key Differentiator: ACU193 showed a significantly lower rate of ARIA compared to other anti-amyloid antibodies, potentially allowing for broader patient access.
Phase 2/3 Study (2024-ongoing)
Development Program:
Phase 2/3 registration-enabling study
Early AD patients (MMSE 22-30)
Primary endpoint: Change in CDR-SB
Secondary endpoints: Biomarkers, PET imaging
Status: Enrollment ongoing as of early 2025
Biomarker Program
Acumen has established robust biomarker capabilities: